Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.
Genetically determined Intellectual Disability (ID) is an intractable condition that involves severe impairment of mental abilities such as learning, reasoning and predicting the future. As of today, little is known about the placebo response in patients with ID.To determine if placebo response exis...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4520690?pdf=render |
id |
doaj-3d7efb35a4164989b2f1f50db2de1614 |
---|---|
record_format |
Article |
spelling |
doaj-3d7efb35a4164989b2f1f50db2de16142020-11-25T01:00:25ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013331610.1371/journal.pone.0133316Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Aurore CurieKathy YangIrving KirschRandy L GollubVincent des PortesTed J KaptchukKarin B JensenGenetically determined Intellectual Disability (ID) is an intractable condition that involves severe impairment of mental abilities such as learning, reasoning and predicting the future. As of today, little is known about the placebo response in patients with ID.To determine if placebo response exists in patients with genetically determined ID.We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO to find all placebo-controlled double-blind randomized clinical trials (RCTs) in patients with genetically determined ID, published up to April 2013, focusing on core ID symptoms.Two investigators extracted outcome data independently.Bias-corrected standardized mean difference (Hedge's g) was computed for each outcome measure, using the Comprehensive Meta-Analysis software. A priori defined patient sub-groups were analyzed using a mixed-effect model. The relationship between pre-defined continuous variable moderators (age, IQ, year of publication and trial duration) and effect size was analyzed using meta-regression.Twenty-two placebo-controlled double-blind RCTs met the inclusion criteria (n = 721, mean age = 17.1 years, 62% men, mean trial duration = 35 weeks). There was a significant overall placebo response from pre- to post-treatment in patients with ID (g = 0.468, p = 0.002), both for "subjective outcomes" (a third-person's evaluation of the patient) (g = 0.563, p = 0.022) and "objective outcomes" (direct evaluation of the patient's abilities) (g = 0.434, p = 0.036). Individuals with higher IQ had higher response to placebo (p = 0.02) and no placebo response was observed in ID patients with comorbid dementia. A significant effect of age (p = 0.02) was found, indicating higher placebo responses in treatment of younger patients.Results suggest that patients with genetically determined ID improve in the placebo arm of RCTs. Several mechanisms may contribute to placebo effects in ID, including expectancy, implicit learning and "placebo-by-proxy" induced by clinicians/family members. As the condition is refractory, there is little risk that improvements are explained by spontaneous remission. While new avenues for treatment of genetically determined ID are emerging, our results demonstrate how contextual factors can affect clinical outcomes and emphasize the importance of being vigilant on the role of placebos when testing novel treatments in ID.http://europepmc.org/articles/PMC4520690?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aurore Curie Kathy Yang Irving Kirsch Randy L Gollub Vincent des Portes Ted J Kaptchuk Karin B Jensen |
spellingShingle |
Aurore Curie Kathy Yang Irving Kirsch Randy L Gollub Vincent des Portes Ted J Kaptchuk Karin B Jensen Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. PLoS ONE |
author_facet |
Aurore Curie Kathy Yang Irving Kirsch Randy L Gollub Vincent des Portes Ted J Kaptchuk Karin B Jensen |
author_sort |
Aurore Curie |
title |
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. |
title_short |
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. |
title_full |
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. |
title_fullStr |
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. |
title_full_unstemmed |
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. |
title_sort |
placebo responses in genetically determined intellectual disability: a meta-analysis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Genetically determined Intellectual Disability (ID) is an intractable condition that involves severe impairment of mental abilities such as learning, reasoning and predicting the future. As of today, little is known about the placebo response in patients with ID.To determine if placebo response exists in patients with genetically determined ID.We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO to find all placebo-controlled double-blind randomized clinical trials (RCTs) in patients with genetically determined ID, published up to April 2013, focusing on core ID symptoms.Two investigators extracted outcome data independently.Bias-corrected standardized mean difference (Hedge's g) was computed for each outcome measure, using the Comprehensive Meta-Analysis software. A priori defined patient sub-groups were analyzed using a mixed-effect model. The relationship between pre-defined continuous variable moderators (age, IQ, year of publication and trial duration) and effect size was analyzed using meta-regression.Twenty-two placebo-controlled double-blind RCTs met the inclusion criteria (n = 721, mean age = 17.1 years, 62% men, mean trial duration = 35 weeks). There was a significant overall placebo response from pre- to post-treatment in patients with ID (g = 0.468, p = 0.002), both for "subjective outcomes" (a third-person's evaluation of the patient) (g = 0.563, p = 0.022) and "objective outcomes" (direct evaluation of the patient's abilities) (g = 0.434, p = 0.036). Individuals with higher IQ had higher response to placebo (p = 0.02) and no placebo response was observed in ID patients with comorbid dementia. A significant effect of age (p = 0.02) was found, indicating higher placebo responses in treatment of younger patients.Results suggest that patients with genetically determined ID improve in the placebo arm of RCTs. Several mechanisms may contribute to placebo effects in ID, including expectancy, implicit learning and "placebo-by-proxy" induced by clinicians/family members. As the condition is refractory, there is little risk that improvements are explained by spontaneous remission. While new avenues for treatment of genetically determined ID are emerging, our results demonstrate how contextual factors can affect clinical outcomes and emphasize the importance of being vigilant on the role of placebos when testing novel treatments in ID. |
url |
http://europepmc.org/articles/PMC4520690?pdf=render |
work_keys_str_mv |
AT aurorecurie placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis AT kathyyang placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis AT irvingkirsch placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis AT randylgollub placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis AT vincentdesportes placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis AT tedjkaptchuk placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis AT karinbjensen placeboresponsesingeneticallydeterminedintellectualdisabilityametaanalysis |
_version_ |
1725213553928962048 |